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Cardiovascular complications are a major cause of mortality
in hemodialysis patients. On-line hemofiltration combines
convective clearance for removing large solutes with
diffusion to remove small solutes and is associated with a
significant reduction of inflammation and improved patient
survival. We compared on-line hemofiltration to high-flux
hemodialysis (HF-HD) in patients in a sequential manner. At
baseline, 15 stable patients on HF-HD as compared with five
control subjects showed significant increases in
CD14þCD16þ cells, endothelial microparticles, and
endothelial progenitor cells (EPCs). After 4 months of on-line
hemofiltration, the number of CD14þCD16þ cells,
microparticles, and EPCs decreased. After returning to HF-HD
for 4 months, all measured parameters returned to their
respective baseline values. The number of CD14þCD16þ
cells correlated with both endothelial microparticles and
EPCs. We conclude that on-line hemofiltration attenuates
endothelial dysfunction possibly by decreasing
microinflammation. This effect may be directly caused by a
modulatory effect of on-line hemofiltration on
proinflammatory cells or by a complex interaction that
encompasses a wider removal of uremic toxins.
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End-stage chronic kidney disease (CKD) is associated with a
high prevalence of cardiovascular complications.1 These CKD
patients suffer from a chronic inflammatory process, which
causes endothelial injury,2 a critical event in the pathogenesis
of atherosclerosis.3,4 Furthermore, in these patients, uremic
toxins and inflammation are more potent predictors of
arteriosclerosis than the classic risk factors such as hyper-
tension, dyslipoproteinemia, obesity, and smoking;5,6 markers
of inflammation such as C-reactive protein and cytokines are
independent predictors of all cause and cardiovascular
mortality.7–9
In the last years, research in the biology of the
endothelium has provided new targets to examine endothe-
lial damage and repair in human pathology. Upon a noxious
insult, endothelial cells may undergo vesiculation ensuing in
the release of microparticles ‘endothelial microparticles’
(EMP) into the bloodstream. EMP express endothelial-
specific surface markers reflective of parent cell status (e.g.,
activated and apoptotic).10 On the other hand, the mobiliza-
tion of bone marrow-derived endothelial progenitor cells
(EPC) is critical for the preservation of the integrity of
endothelium.11 Endothelial repair requires the presence of
EPC, which originate from the bone marrow as demonstrated
by the expression of CD34 (a surface marker common to
hematopoietic stem cells and mature endothelial cells) and
vascular endothelial cell growth-factor receptor 2 (VEGFR2
or kinase domain-related (KDR) receptor).12 Several studies
have shown evidence of endothelial damage and dysfunction
in hemodialysis patients. Increased levels of apoptotic EMP
have been reported in plasma from CKD-5 patients. In
addition, several authors have reported that in CKD-4–5
patients there is a decrease in EPC;13 however, these findings
are not uniform as other groups have reported a normal14 or
even increased number of circulating EPC.15
The potential for reversal of vascular disease in CKD-5
patients is unknown. The quality and technology of
hemodialysis have improved in relation to biocompatibility
of the materials used and the ability to remove larger size
uremic toxins molecules. By combining ultrafiltration (con-
vective clearances for removing larger solutes) with diffusion
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(for removal of small solutes), on-line hemodialfiltration
(OL-HDF) offers a highly effective dialysis modality expand-
ing the spectrum of removed uremic toxins from small to
middle-sized molecular solutes. Recently, OL-HDF has been
associated with a significant reduction of inflammation and
improved survival.16,17 The aim of this study was to examine
whether amelioration of microinflammation using OL-HDF
has an effect on EMP and ECP as biomarkers of endothelial
injury and repair, respectively.
RESULTS
Patients
Table 1 illustrates the characteristics and laboratory data of
patients included in the study at baseline. These parameters
remained unchanged during the study.
Evaluation of CD14 and CD16 mononuclear expression
As compared with normal subjects, at baseline (after 2
months on high-flux hemodialysis (HF-HD)), CKD-5
patients exhibited a high percentage of peripheral blood
mononuclear cells (PBMC) positive for CD14 and CD16 as
compared with healthy controls (20.372.3% vs 4.572.5%;
P¼ 0.001). After 4 months on OL-HDF, these same patients
showed a marked decrease in the percent of CD14þCD16þ
cells (14.973.2%, P¼ 0.001). A decrease in CD14þCD16þ
cells after OL-HDF was observed in all 15 patients. During
the following period, (back to HF-HD), the percent of
CD14þCD16þ cells increased to 19.272.8% (Po0.001 vs
OL-HDF) (Table 2).
Evaluation of CD31þ /Annexin Vþ EMP and EPC
As observed in a representative histogram from the
flowcytometer (Figure 1), samples from HF-HD patients at
baseline showed an increased number of EPC annexin-Vþ /
CD31þ as compared with healthy subjects. In addition, in
PBMC from HF-HD patients at baseline the percentage of
CD31, CD14, and VEGFR2 EPC is increased as compared
with controls (Figure 2).
Patients on HF-HD (baseline) presented a high number of
EMP events (21.377.4 events/ml vs controls, P¼ 0.001,
Figure 3a). After 4 months on OL-HDF, the number of
events significantly decreased in all but one patient
(15.475.5 events/ml, P¼ 0.045 vs baseline). During the
following 4 months of HF-HD, the number of events
increased in all patients to 20.976.0 events/ml, a level
superimposable to that of baseline.
Figure 3b shows a high percentage of EPC in HF-HD
patients at baseline in comparison with controls
(30.877.1%, P¼ 0.001). After 4 months on OL-HDF, the
number of events significantly decreased to 20.875.4%
(P¼ 0.001 vs baseline). In the following 4 months of HF-HD,
the number of EPC returned to a level superimposable to that
of baseline (29.274.0, P¼ 0.001 vs OL-HDF, P¼ 0.9 vs
baseline).
Table 1 | Characteristics and laboratory values of the included
patients at baseline
Parameters HF-HD Basal
Number of patients 15
Gender, male/female 11/4
Age (year; mean, minimum–maximum) 55 (22–77)
Dialysis vintage (months; mean, minimum–maximum) 49 (14–122)
Duration of dialysis treatment (minutes; mean,
minimum–maximum)
226 (180–272)
eKt/V (mean, minimum–maximum) 1.39 (1.08–1.88)
Leucocytes (mean, minimum–maximum) 7870.51.7 (4520–11425)
Hemoglobin (g/dl; mean, minimum–maximum) 12.12 (9.2–14)
Ferritin (mcg/ml, mean, minimum–maximum) 481.4 (159–877)
Albumin (gr/dl; mean, minimum–maximum) 4.06 (3.7–4.5)
CRP (mg/l; median, minimum–maximum) 2 (0.7–9.1)
Plasma TNF (pg/ml; mean, minimum–maximum) 41.9 (33.2–52.9)
Plasma IL-6 (pg/ml; mean, minimum–maximum) 18.9 (10.6–17.8)
b2-microglobulin (mean, minimum–maximum) 27.2 (19–39.5)
PO4 (mg/dl; mean, minimum–maximum) 5.24 (3.3–7.5)
Ca (mg/dl; mean, minimum–maximum) 9.4 (8.1–10.8)
Ca PO4 (mg
2/dl2; mean, minimum–maximum) 48.99 (38.9–66.6)
EPO dosage (mg) 33.84 (10–80)
CRP, C-reactive protein; EPO, erythropoietin; IL-6, interleukin-6; TNF, tumor necrosis
factor.
Table 2 | Mononuclear expression of CD14 and CD16 in
patients during the study periods
HF-HD baseline OL-HDF HF-HD
CD14++ 80.475.7 85.672.8* 79.173.6
CD14+CD16+ 20.372.3 14.973.2* 19.272.8
All data are expressed as means7s.d. from 15 patients studied.
*Po0.001 vs HF-HD baseline and HF-HD.
1000a b
c d
800
H
ea
lth
y 
su
bje
cts
H
F-
H
D
 b
as
el
in
e
600
SS
C 
he
ig
ht
An
ex
in
a.
 
V
SS
C 
he
ig
ht
An
ex
in
a.
 
V
400
200
1000
800
600
400
200
1000
800
600
400
200
1000
800
600
400
200
0 200 400 600
FSC height CD31FITC
FSC height CD31FITC
800 1000
0 200 400 600 800 1000 0 200 400 600 800 1000
0 200 400 600 800 1000
R.1
R.1
Figure 1 | Phenotype of endothelial microparticles (EMP).
Representative graphs of cytofluorometry analysis of EMP in platelet-
free plasma from healthy subjects (a and b) and patients in HF-HD at
baseline (c and d). (a and c) EMP are represented on a forward
scatter/side-scatter dot-plot histogram. EMP are defined as events,
with a size of 0.1–1 mm, and are gated in R1 window. (b and d) Size-
selected events are plotted as a function of their double fluorescence
for CD31-FITC and specific Annexin-PE binding.
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Correlation between microinflammation (CD14þCD16þ
cells) and endothelial damage (EMP and EPC)
Interestingly, the number of CD14þCD16þ cells correlated
significantly with both EMP (r¼ 0.63, P¼ 0.003; Figure 4a)
and EPC (r¼ 0.57, P¼ 0.004; Figure 4b) in blood samples
from HF-HD and OL-HDF. However, there was no
correlation between EPC and EMP (data not shown).
To evaluate the effects of one dialysis session of each
modality on endothelial damage, EPC and EMP were
evaluated before and after a treatment session at the
beginning of each of the two periods. Although EMP
increased significantly at the end of HF-HD (at both, baseline
and after the last 4 months on HF-HD), no significant
changes occurred after OL-HDF. A significant reduction of
EPC was observed in both HF-HD and in OL-HDF
(Figure 5). These results could not be attributed to a
dilutional effect, as net fluid balance was not different in both
procedures.
DISCUSSION
Our results clearly show that a significantly high number of
circulating CD31þ /Annexin Vþ EMP were observed in
patients on HD-HF as compared with healthy controls. The
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Figure 2 | Phenotype of endothelial progenitor cells (EPC).
Representative graphs of cytofluorometry analysis of EPC in blood
from healthy subjects (a and b) and patients in HF-HD at baseline
(c and d). The phenotype of EPC as indicated by triple-positive for
CD31, CD14, and VEGFR2. (a and c) VEGFR2 are represented on
a histogram of fluorescence, and are gated in R1 window.
(b and d) Positive events for VEGFR2 (R1 gated) are plotted as a
function of their fluorescence for CD14 and CD31.
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Figure 3 | Evaluation of EMP and EPC during study periods.
(a) EMP at baseline patients on HF-HD (21.377.4 events/ml), after
4 months on OL-HDF (15.475.5 events/ml), and after 4 months in
HF-HD (20.976.0 events/ml). *P¼ 0.045, OL-HDF vs baseline HF-HD,
P¼ 0.048 HF-HD vs OL-HDF). The open circles represent the values for
EMP in healthy subjects. (b) EPC at baseline patients on HF-HD
(30.877.1%), after 4 months on OL-HDF (20.875.4%), and after
4 months in HF-HD (29.274.0%). *Po0.001, OL-HDF vs baseline
HF-HD, Po0.001 HF-HD vs OL-HDF). The open circles represent the
values for EMP in healthy subjects.
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Figure 4 | Correlation between CD14þCD16þ cells and EMP or
EPC. (a) CD14þCD16þ cells percent were correlated with the
number of EMP of patients in HF-HD in baseline (closed circles) and
OL-HDF (open circles). (b) CD14þCD16þ cells percent were
correlated with the number of EPC of patients in HF-HD in baseline
(closed circles) and OL-HDF (open circles).
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Figure 5 | Evaluation of EMP and EPC after a treatment session.
EMP (a) and EPC (b) at baseline patients on HF-HD, after 4 months on
OL-HDF, and after 4 months in HF-HD. The black bars represents
values before treatment session HD, and the empty bars are values
after HD session. (a) EMP increased after hemodialysis session in both
group of patients in HF-HD but not in OL-HDF. *P¼ 0.002,
**P¼ 0.007. (b) A significant reduction in EPC was observed in both
HD-HF and in OL-HDF. *P¼ 0.021, **P¼ 0.001, #P¼ 0.018.
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elevated number of EMP was associated with an also
remarkably high count of EPC. Both circulating EMP and
EPC were reduced after 4 months of OL-HDF.
This study confirms our previously published data on the
reduction of proinflammatory CD14þCD16þmonocyte-
derived dendritic cells in patients on OL-HDF.17 This study
shows that the rise of CD14þCD16þ cells is associated with
proportional increases in both ECM and EPC.
An emerging interest has been drawn from recent human
studies underlying the association of EMP to endothelial
dysfunction and arterial dysfunction in CKD.18,19 By the
linear regression analysis, we documented a significant
correlation between proinflammatory CD14þCD16þ cells,
and both the number of EMP as well as the number of EPC.
It is tempting to speculate that CD14þCD16þ monocyte-
derived dendritic cells may have a dual effect triggering
endothelial activation and injury leading to the release of
EMP and the stimulation of the bone marrow to increase the
production of circulating EPC. We were unable to claim a
direct cause-and-effect relationship between microinflamma-
tion, formation of EMP, and increased numbers of circulating
EPC. Other factors such as uremic toxins, or other activated
cells (e.g., platelets, leukocytes) may come into play. Jacobi
et al.20 have implicated the priming of polymorphonuclear
neutrophils as the main mechanism of the initiation of
endothelial injury.
It is of interest that no increase in EMP was observed in
postdialysis blood samples after OL-HDF. In all cases, HF-
HD was associated with a remarkable increase of EMP. In
both HF-HD and OL-HDF, EPC decreased significantly in
the postdialysis blood samples in respect to the predialysis
ones. The unique relevance of convection on the observed
changes was due to the fact that both dialysis modalities, HD-
HF and OL-HDF were in fact equal for the membrane used
and water quality. To insure uniform procedures and quality
standards, we performed these studies in one single center.
Our study shows, for the first time, that reduction of the
monocyte subpopulation responsible for cytokine produc-
tion by OL-HDF may decrease the damage of the
endothelium.
Our study has a number of limitations. First, the lack of
randomization of the patients to different sequences of
treatments might in principle have left the potential for
residual confounding by unrecognized factors or cointerven-
tions over time. However, as in our previous publication, also
in the present studies we observed that the percent of
CD14þ /CD16þ cells was not changed after 4 months of
HF-HD (first and third period), thus attenuating a major
impact by time and/or seasonal factors. Second, although
EPM and EPC are considered as markers of endothelial
damage and repair, respectively, they cannot be considered as
surrogate measures for cardiovascular outcome. Further-
more, there are controversies on the identification, definition,
and significance of EPC in the pathophysiology of different
diseases. According with Ingram et al.,12 our EPC were
sorted by three monoclonal antibodies anti-CD14, -CD31,
and -VEGFR2. The latter has been shown to be expressed on
peripheral blood cells that proliferate in vivo and that
contribute to re-endothelialization. Recent studies also
suggest that circulating detached endothelial cells and
stimulated EPC from the bone marrow may reflect
endothelial injury.21,22 In this study, we did not assess the
plasma levels of VEGF, a stimulus for EPC release from bone
marrow. Therefore, we cannot exclude that VEGF levels may
have some responsibility of the observed changes. Also
erythropoietin (EPO) is a strong stimulus for EPC release.
However, there was no significant change in the routine EPO
dose in any of the patients throughout the study period.
Third, the effect of OL-HDF was only 15%, whereas the
difference between patients and healthy controls was far more
substantial (400% higher levels in patients than in healthy
subjects). Even the most effective dialysis technique (OL-
HDF) was far from producing a biologically relevant effect on
endothelial dysfunction. Nevertheless, one must remember
that the patient population was selected to identify patients
who had no signs or symptoms as well as laboratory markers
of an ongoing overt inflammation (as shown by stably low
C-reactive protein and EPO dose during the 8-month follow
up. In a cross-sectional study, Chan et al.15 showed the
normalization of EPC counts and function in patients on
nocturnal daily hemodialysis for at least 1 year.
Finally, the uremic milieu may also play a role. Faure
et al.19 evaluated the effect of specific uremic factors on EMP
release in vitro, and showed that some uremic toxins such as
p-cresol and indoxyl sulfate are able to induce the vesicula-
tion of cultured endothelial cells. Bammens et al.23 showed
that OL-HDF significantly reduces the levels of p-cresol in
respect to HF-HD, thus possibly suggesting an effect of high
convective transfer in the removal of a wider spectrum of
uremic toxins than that observed in predominantly diffusive
therapies such as HF-HD.
The beneficial effect of high convective transport
(OL-HDF) may be directly caused by modulation of
proinflammatory CD14þCD16þ monocyte-derived den-
dritic cells or by a more complex interaction that also
encompasses removal of a wider spectrum of uremic toxins.
Whatever the mechanism/s might be at work, OL-HDF is
associated with less formation of EMP and release of EPC in
the circulation.
In conclusion, our studies provide the evidence that
microinflammation is associated to endothelial damage and
that amelioration of the microinflammatory status using high
convective transport appears to reduce endothelial damage.
Further studies will need to warrant whether long-term OL-
HDF attenuates endothelial dysfunction and microinflamma-
tion in patients with overt systemic inflammation and
whether this can be associated to the improved survival.
MATERIALS AND METHODS
Study design
A total of 15 stable HD patients were included. All patients had been
treated for more than 6 months in the satellite dialysis facility of
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Reina Sofia University Hospital of Cordoba and remained in the
same facility throughout the study. The same group of patients was
sequentially treated with two different modalities of HD during 4
months each: HF-HD and OL-HDF. Both procedures are regularly
used in patients on maintenance hemodialysis; however, OL-HDF
offers more convective transport, which results in removal of a wider
spectrum of uremic toxins. All patients were on HF-HD during at
least 2 months (baseline), then, patients were switched to OL-HDF
for an additional period of 4 months and finally patients were
changed back to HF-HD for 4 months. Five apparently healthy
subjects (age: 4976 years; gender: male 3/female 2) were studied.
Patient and baseline data
At baseline all patients were on HF-HD using polysulfone
membranes (1.8 m2, HF80, Fresenius Medical Care, Bad Homburg,
Germany) using 4008 dialysis monitors (Fresenius Medical Care).
HF-HD and OL-HDF were performed with ultrapure bicarbonate-
buffered dialysate three times a week. The average volume of on-line
reinfusion fluid per session was 19.7 l (range: 17.0–24.1). Analysis of
the dialysis system always revealed absence of bacteria (o100 cfu/ml
(colony-forming units/milliliter)) or bacteriological contaminant
products (endotoxin levels below 0.025 endotoxin units) during the
whole period of the study. The dialysis characteristics were similar in
the two modalities, the only difference being a higher convective
transport in the OL-HDF than HF-HD. The therapeutic regime
consisted in EPO, calcium-containing phosphate binders, antihy-
pertensive drugs, and intravenous iron. All patients were on EPO
from the beginning of the study. EPO dosage was adjusted to
maintain the hemoglobin target of 11.5–12 g/dl. Weekly EPO dose
was similar in both modalities of HD along the study. Patients with
symptoms or signs of inflammation, infection, and cancer were
excluded. None of the patients were on anti-inflammatory or
immunosuppressive drugs during the 3 months before inclusion and
for the whole period of the study. None of them had diabetes.
Informed consent was obtained from all patients. All routine
laboratory measurements were done using certificate assay methods.
The effect of each experimental period was assessed, by obtaining
the blood samples just before the first dialysis session of the
following study period. To analyze the effects of one dialysis session
of each dialysis modalities (HF-HD and OL-HDF), blood samples
were obtained just before and after the corresponding first weekly
dialysis session.
Experimental procedures
Human mononuclear cell culture. PBMC and plasma were
obtained from 20 ml of citrate-buffered blood drawn immediately
before dialysis session. To analyze the effect of a single dialysis
procedure, blood samples were obtained before and after comple-
tion of the dialysis session. Buffy coat cells were separated by
differential centrifugation gradient (Ficoll/Hypaque; Pharmacia
LKB, Uppsala, Sweden). Thereafter, cells were washed and seeded
in 12-well at 371C in complete culture medium containing RPMI-
1640 supplemented with L-glutamine (2 mM), Hepes (20 mM),
sodium pyruvate (1 mM), streptomycin (50 ng/ml), penicillin
(100 UI/ml), and 10% human autologous serum (Bio-Whittaker,
Walkersville, MD, USA). Serum was heated (561C, 60 min) to
inactivate complement.
Cytometric bead array immunoassay. The amount of cyto-
kines in plasma was evaluated using a Cytometric bead array
immunoassay. The cytometric bead array technique was based on
the binding of microparticles labeled with different fluorescence
intensities to antibodies. The maximum wavelength emission was
about 650 nm (fluorescence-3 channel). The particles were bound by
a covalent bond to an antibody against one of the cytokines tumor
necrosis factor-a or interleukin-6 (Pharmingen, San Diego, CA,
USA). This method allowed the simultaneous determination of
different cytokines in the same sample. The cytokines were captured
directly in the immunoassay using different antibodies bound to
phycoerythrin (PE), which emitted at 585 nm (fluorescence-2
channel). The PE-conjugated detector antibody completed the
sandwich, and the intensity measured in fluorescence-2 channel was
proportional to the concentration of cytokines in the sample, which
was quantified from a calibration curve. An important characteristic
of the assay system was that the calibrators, the antibody–bead
reagent, and the second antibody reagent, antibody–PE were made
from mixtures of cytokines. Standard curves (0–5000 pg/ml) were
derived from a set of calibrators and the same set was used for all
assays. Then, 50 ml of the sample or cytokine standard was added to
the mixture of 50 ml each of antibody–PE detector and antibody–-
bead reagent. The mixture (150 ml) was incubated for 160 min in the
dark at room temperature, washed, and the test samples were
acquired using the flow cytometer.
Evaluation of CD14 and CD16 mononuclear expression. To
quantify proinflammatory cells (CD14þCD16þ ) a sample of
105/ml PBMC was incubated during 30 min, at 41C with the
monoclonal antibodies (Mab) M5E2 against the molecule CD14 and
3G8 against the molecule CD16 (Becton Dickinson, San Jose´, CA,
USA). Cytofluorometric analysis was performed with a FACSCalibur
cytometer (Becton Dickinson).
Determination. of CD31þ /Annexin Vþ EMP. Apoptotic ECM
were isolated as described earlier.10 Plasma derived from 20-ml
citrate-buffered blood was separated from whole blood and
immediately centrifuged at 13 000 g for 5 min to generate platelet-
poor plasma. Platelet-poor plasma (50 ml) was incubated with 4 ml of
monoclonal antibody against CD31 (MHCD3104-PE Caltag Lab,
Burlingame, CA, USA) followed by incubation with fluorescein
isothiocyanate-conjugated Annexin V kits according to the manu-
facturer’s instructions (Bender MedSystem, Vienna, Austria).
Fluorescence-activated cell sorter analysis was performed in a
FACSCalibur cytometer. The negative control (zero value) was the
value obtained using the isotype antibodies. Each result (one single
value) was the average of three independent determinations of the
same sample.
Characterization of EPC. The EPCs were defined as cells triple-
positive for CD31, CD14, and VEGFR2.12 Previous studies have
demonstrated that these cells are actively involved in endothelial
repair.12.Immediately after blood extraction, PBMC were separated
by Ficoll, washed with phosphate-buffered saline, and resuspended
in EBM-2 medium supplemented with antibiotics and 20% of fetal
bovine serum. Thereafter 2 106 cells were incubated for 30 min in
the dark at 41C with saturating concentrations of the following
monoclonal antibodies (mAb): anti-VEGFR2 (antihuman VEGFR2
KDR-PE; R&D System, Minneapolis, MN USA), anti-CD31
(MHCD3101FITC, Caltag Lab), and anti-CD14 (MHCD1406TRI-
COLOR) and corresponding isotype controls. Then, cells were
washed with phosphate-buffered saline, and the test samples were
analyzed using the flow cytometer. Quantitative analysis was
performed on a FACSCalibur cytometer (Becton Dickinson)
measuring 200 000 events per sample. Data were analyzed using
CELLQuest software (Becton Dickinson) by side scatter-fluorescence
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dot plot analysis. The number of EPCs was defined as events triple-
positive for CD31, CD14, and VEGFR2. The negative control (zero
value) was the value obtained using the isotype antibodies. Each
result (one single value) was the average of three independent
determinations of the same sample.
Statistical analysis. Comparison between means from different
periods was performed by repeated measures analysis of variance
followed by Bonferroni test. The comparison of two means was done
by Student’s t-test for paired data. Non-parametric data were
analyzed by Wilcoxon or Mann–Whitney test for paired and
unpaired comparison, respectively. The Spearman rank correlation
coefficient was used to analyze correlation. Differences were
considered significant when Po0.05.
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